Solid Biosciences SLDB
NASDAQ SLDB
$6.18 -0.23 (-3.67%)
As of: Oct 22, 2026 · 3:54 PM EDT

Solid Biosciences (SLDB) Receivables - Other (2020 - 2022)

Updated

Solid Biosciences (SLDB) recorded Receivables - Other of $14,000 in Q1 2022, down 95.0% from $280,000 a year earlier and down 87.3% from the prior quarter.

Analysis

Solid Biosciences (SLDB) Receivables - Other (2020 - 2022) Analysis & Trends

At the end of FY2021, Solid Biosciences reported Receivables - Other of $110,000.

  • Per Business Quant, the preceding three quarters came in at $110,000 (Q4 2021), $594,000 (Q3 2021) and $286,000 (Q2 2021).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,165.22 Bn 1,133.81 Bn 19.71 Bn
2 Johnson & Johnson 646.28 Bn 566.14 Bn 17.30 Bn
3 AbbVie 503.17 Bn 476.28 Bn 12.70 Bn
4 Merck 365.23 Bn 319.60 Bn 12.21 Bn
5 Novartis Ag 302.66 Bn 266.65 Bn 11.24 Bn
6 Astrazeneca 267.39 Bn 241.08 Bn 12.86 Bn
7 Amgen 241.61 Bn 197.01 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 172.91 Bn 119.55 Bn 10.94 Bn
10 Solid Biosciences 887.28 Mn -295.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2022 14,000.00
Dec 31, 2021 110,000.00
Sep 30, 2021 594,000.00
Jun 30, 2021 286,000.00
Mar 31, 2021 280,000.00
Jun 30, 2020 286,000.00
API Access

Solid Biosciences Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=SLDB&period=max&api_key=YOUR_API_KEY